Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Beer

Showing results (821-830 of 888) with videos related to

Pageof 89
Sort By:
Lancet (London, England)|April 20, 2010
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyHoward I Scher, Tomasz M Beer, Celestia S Higano, et al.
European Urology|January 12, 2020
Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized StudyDaniel W Lin, Mei-Chiung Shih, William Aronson, et al.
Journal of the National Cancer Institute|December 6, 2017
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate CancerAlexander W Wyatt, Matti Annala, Rahul Aggarwal, et al.
Science (New York, N.Y.)|April 11, 2009
Development of a second-generation antiandrogen for treatment of advanced prostate cancerChris Tran, Samedy Ouk, Nicola J Clegg, et al.
Journal for Immunotherapy of Cancer|December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinomaDouglas G McNeel, Neil H Bander, Tomasz M Beer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupHoward I Scher, Susan Halabi, Ian Tannock, et al.
Molecular Cancer Research : MCR|March 29, 2019
Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass HeterogeneityRahul R Aggarwal, David A Quigley, Jiaoti Huang, et al.
Clinical Genitourinary Cancer|June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate CancerTerence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
European Urology|August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyTomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT InvestigatorsTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Pageof 89

Showing results (821-830 of 888) with videos related to

Sort By:
Pageof 89
Lancet (London, England)|April 20, 2010
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyHoward I Scher, Tomasz M Beer, Celestia S Higano, et al.
European Urology|January 12, 2020
Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized StudyDaniel W Lin, Mei-Chiung Shih, William Aronson, et al.
Journal of the National Cancer Institute|December 6, 2017
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate CancerAlexander W Wyatt, Matti Annala, Rahul Aggarwal, et al.
Science (New York, N.Y.)|April 11, 2009
Development of a second-generation antiandrogen for treatment of advanced prostate cancerChris Tran, Samedy Ouk, Nicola J Clegg, et al.
Journal for Immunotherapy of Cancer|December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinomaDouglas G McNeel, Neil H Bander, Tomasz M Beer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupHoward I Scher, Susan Halabi, Ian Tannock, et al.
Molecular Cancer Research : MCR|March 29, 2019
Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass HeterogeneityRahul R Aggarwal, David A Quigley, Jiaoti Huang, et al.
Clinical Genitourinary Cancer|June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate CancerTerence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
European Urology|August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyTomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT InvestigatorsTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Pageof 89